SecBot SecBot
SC 13D ·Filed Oct 26, 2026
CT

CTY

CITY THERAPEUTICS, INC.
NEUTRAL
Impact 5/10
Processed16h 15m ago SEC0001193125-26-432028
Activist investor acquires 5%+ stake

Price Chart

Loading chart...

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13D Filing (Primary)0001193125-26-432028
Document: 0001193125-26-432028-index-headers.html0001193125-26-432028
Document: 0001193125-26-432028-index.html0001193125-26-432028
Document: 0001193125-26-432028.txt0001193125-26-432028
18 reports for CTY
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for CTY — sortable, filterable
TypeNow
Oct 26, 2026
today
SC 13D
NEUTRAL ★ 5/10
$20.79awaiting T+1—$20.79 (+0.00%)
Oct 26, 2026
today
SC 13G
NEUTRAL ★ 4/10
$20.79awaiting T+1—$20.79 (+0.00%)
Oct 22, 2026
4d ago
SC 13G
NEUTRAL ★ 3/10
$20.77 $20.77· 0.00%▲ +0.52%$20.79 (+0.10%)
Oct 19, 2026
7d ago
Insider Cluster
BULLISH ★ 6/10
$20.83 $20.43▼ −1.92%▼ −2.45%$20.79 (−0.19%)
Oct 19, 2026
7d ago
Press Release
NEUTRAL ★ 5/10
$20.83 $20.43▼ −1.92%▼ −2.45%$20.79 (−0.19%)
Oct 16, 2026
10d ago
424B4
NEUTRAL ★ 5/10
$21.46 $20.83▼ −2.94%▼ −3.27%$20.79 (−3.12%)
Oct 16, 2026
11d ago
EFFECT
NEUTRAL ★ 5/10
$22.40 $21.46▼ −4.20%▼ −4.62%$20.79 (−7.19%)
Oct 15, 2026
11d ago
3
NEUTRAL ★ 3/10
$22.40 $21.46▼ −4.20%▼ −4.62%$20.79 (−7.19%)
Oct 15, 2026
11d ago
3
NEUTRAL ★ 2/10
$22.40 $21.46▼ −4.20%▼ −4.62%$20.79 (−7.19%)
Oct 15, 2026
11d ago
3
NEUTRAL ★ 2/10
$22.40 $21.46▼ −4.20%▼ −4.62%$20.79 (−7.19%)
Showing 10 of 18

US Market Status

Market Closed — Opens in 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 26, 2026

Fresh CTY Intelligence

Analysis is for subscribers only.

Subscribe for Full Access